Anti-Human CD261/TNFRSF10A/DR4 Antibody (SAA2670) from ProteoGenix; catalogue ARO-A23213; research use only.
Know who made it. See the evidence. Buy through one marketplace.
A highly specific and potent tool for your biotech research needs.
This antibody targets the CD261/TNFRSF10A/DR4 protein, a member of the tumor necrosis factor (TNF) receptor superfamily. CD261/TNFRSF10A/DR4 is a cell surface receptor that plays a crucial role in the regulation of apoptosis, or programmed cell death. It is involved in various cellular processes, including immune response, tissue development, and maintenance of homeostasis.
The Anti-Human CD261/TNFRSF10A/DR4 Antibody (SAA2670) has been extensively tested and validated for its high specificity and sensitivity towards the CD261/TNFRSF10A/DR4 protein. It has been shown to effectively block the binding of TNF-related apoptosis-inducing ligand (TRAIL) to CD261/TNFRSF10A/DR4, thereby inhibiting the apoptotic signaling pathway.
This antibody is a valuable tool for studying the role of CD261/TNFRSF10A/DR4 in various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. It can also be used to investigate the therapeutic potential of targeting CD261/TNFRSF10A/DR4 in these conditions.
The Anti-Human CD261/TNFRSF10A/DR4 Antibody (SAA2670) has been successfully used in a variety of experimental techniques, including western blotting, immunoprecipitation, and immunofluorescence. Its high specificity and sensitivity make it an ideal choice for detecting and quantifying CD261/TNFRSF10A/DR4 expression in different cell types and tissues.
In summary, the Anti-Human CD261/TNFRSF10A/DR4 Antibody (SAA2670) is a reliable and powerful tool for studying the function of CD261/TNFRSF10A/DR4 in various biological processes. Its applications range from basic research to potential therapeutic interventions, making it a valuable addition to any biotech laboratory. Order now and advance your research with confidence.
ProteoGenix catalogue number ARO-A23213. For research use only.
Target: APO2, CD261, DR4, Death receptor 4, TNF-related apoptosis-inducing ligand receptor 1, TNFRSF10A, TRAIL receptor 1, TRAIL-R1, TRAILR1, Tumor necrosis factor receptor superfamily member 10A; Clonality: Monoclonal Antibody; Reactivity: Human; Applications: Flow Cyt, ELISA.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Species | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Human |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
